MedPath

RxSight

🇺🇸United States
Ownership
-
Employees
374
Market Cap
-
Website
Introduction

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded on March 5, 1997 and is headquartered in Aliso Viejo, CA.

Clinical Trials

8

Active:0
Completed:7

Trial Phases

1 Phases

Not Applicable:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Not Applicable
5 (100.0%)

RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study

Not Applicable
Completed
Conditions
Cataract
Aphakia
First Posted Date
2022-01-24
Last Posted Date
2025-04-20
Lead Sponsor
RxSight, Inc.
Target Recruit Count
500
Registration Number
NCT05202808
Locations
🇺🇸

Slade & Baker Vision, Houston, Texas, United States

🇺🇸

Vold Vision, Fayetteville, Arkansas, United States

🇺🇸

Reeve Woods Eye Center, Chico, California, United States

and more 10 locations

Single Center Exploratory Study To Evaluate The Use Of The RxSight Light Adjustable Lens (LAL) And The Light Delivery Device (LDD) To Improve Visual Outcomes

Completed
Conditions
Cataract
Aphakia
First Posted Date
2020-08-27
Last Posted Date
2025-02-10
Lead Sponsor
RxSight, Inc.
Target Recruit Count
79
Registration Number
NCT04529616
Locations
🇲🇽

CODET Vision Institute, Tijuana, Mexico

A Clinical Study to Evaluate The Safety and Effectiveness of The RxSight Light Adjustable Lens (LAL) In Subjects Desiring an Extended Depth of Focus

Terminated
Conditions
Aphakia
Cataract
Presbyopia
First Posted Date
2019-11-26
Last Posted Date
2025-01-07
Lead Sponsor
RxSight, Inc.
Target Recruit Count
34
Registration Number
NCT04177771
Locations
🇺🇸

Vold Vision, Fayetteville, Arkansas, United States

A Clinical Study to Evaluate The Safety and Effectiveness of Performing 0.50 Diopter Astigmatism Correction on the Commercially Available RxSight Light Adjustable Lens (LAL)

Not Applicable
Completed
Conditions
Aphakia
Cataract
First Posted Date
2019-07-02
Last Posted Date
2021-06-11
Lead Sponsor
RxSight, Inc.
Target Recruit Count
25
Registration Number
NCT04005586
Locations
🇺🇸

Cleveland Eye Clinic, Brecksville, Ohio, United States

🇺🇸

Vance Thompson Vision Clinic, Sioux Falls, South Dakota, United States

Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes

Completed
Conditions
Aphakia
Cataract
First Posted Date
2019-03-29
Last Posted Date
2022-05-12
Lead Sponsor
RxSight, Inc.
Target Recruit Count
66
Registration Number
NCT03895034
Locations
🇲🇽

CODET Vision Institute, Tijuana, Mexico

  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath